The appeal process for denied reimbursement applications in Japan involves resubmitting the application with additional evidence to address MHLW or Chuikyo concerns. Manufacturers must provide stronger clinical, safety, or cost-effectiveness data. Engaging with local agents or consultants is common to navigate the process. Appeals must align with NHI guidelines for reconsideration.
